On the other hands, in patients with unresectable HCC, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib [27], so combination therapy of anti-VEGF/MTA and anti-PD-1/PD-L1 blockade might be new first-line treatment option for patients with unresectable HCC instead of sorafenib or lenvatinib. Here, PDCD1 is linked to hepatocellular carcinoma.